Recently, many hospitals have been performing high-risk HPV testing on general patients as a routine screening tool for initial diagnosis. According to the principles of cervical cancer screening, HPV testing should not be done without cervical cytology (i.e., TCT) because HPV infection is common among sexually active women, about 10%, and most women will heal on their own without special treatment. If HPV testing is performed without TCT, it will needlessly increase the burden on the patient and cause a great deal of psychological burden on the woman who tests positive, leading to a series of unnecessary treatments. Interferon for vaginal use is currently considered to be effective in treating HPV infection, but it is not definitive and is not used as standard of care. The correct screening procedure is to perform a TCT test, which is not needed to test for HPV if the TCT is not abnormal. This is because studies have shown that ASCUS is an atypical manifestation of squamous cells and its significance is unclear. For patients with ASCUS and HPV negative, they have less chance to develop cervical cancer, so colposcopy is not recommended, and repeat TCT is recommended every 3-6 months. If the TCT results are higher than ASCUS lesions, such as ASC-H, LSIL, HSIL, etc. then colposcopy is recommended directly and therefore HPV testing is not needed. In summary, HPV testing is only an adjunct to whether colposcopy and cervical biopsy are recommended in the case of ASCUS on TCT, and should not be used as a routine initial screening tool. Please do not mistake the exaggerated role of certain medical structures for HPV infection and waste a lot of money and time, causing heavy financial and psychological burden.